Floatz logo

PADOPORFIN

Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure

STEBA FranceSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

514 Active assets in the Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
VIPIVOTIDE TETRAXETAN
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

PADOPORFIN is also rated in:

prostate cancerDormant
B
Indicative ·
59 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
54 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →